Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2021; 13(9): 1132-1142
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1132
Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
Ankit Jain, Shivakumar Chitturi, Geoffrey Peters, Desmond Yip
Ankit Jain, Geoffrey Peters, Desmond Yip, Department of Medical Oncology, The Canberra Hospital, Garran 2605, ACT, Australia
Ankit Jain, Shivakumar Chitturi, Geoffrey Peters, Desmond Yip, ANU Medical School, Australian National University, Canberra 0200, ACT, Australia
Shivakumar Chitturi, Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra 2605, ACT, Australia
Author contributions: Jain A and Yip D contributed concept and design, analysis and interpretation of data; Jain A, Chitturi S, Peters G and Yip D wrote the manuscript, and approved the final manuscript.
Conflict-of-interest statement: None of the authors report any conflict-of-interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ankit Jain, DM, DNB, FRACP, MBBS, MCLAM, MD, Staff Specialist, Department of Medical Oncology, The Canberra Hospital, Building 19, Level 5, Yamba Drive, Garran 2605, ACT, Australia. ankit.jain@anu.edu.au
Received: April 7, 2021
Peer-review started: April 7, 2021
First decision: June 15, 2021
Revised: June 27, 2021
Accepted: August 9, 2021
Article in press: August 9, 2021
Published online: September 27, 2021
Processing time: 167 Days and 11.7 Hours
Core Tip

Core Tip: There are several articles about the role of atezolizumab and bevacizumab combination in advanced unresectable hepatocellular carcinoma. However, this mini review focuses on practical issues for clinicians using this combination in hepatocellular carcinoma (HCC) patients with focus on indications, data from recent trials, criteria for selection of appropriate patients for this combination, sequencing strategies, overlapping toxicities, issues with Child Pugh B cirrhosis patients, future role in adjuvant settings and dealing with special subsets of HCC population.